Purpose: To review clinical outcomes of patients with chronic limb ischemia and TASC type
C lesions treated with sirolimus-eluting versus bare SMART nitinol self-expanding stents …

Background—This randomized controlled trial evaluated clinical durability of Zilver PTX, a
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …

Background Because stent implantation for disease of the superficial femoral artery has
been associated with high rates of late clinical failure, percutaneous transluminal …

Purpose To compare the performance of drug-coated balloons (DCB) and drug-eluting
stents (DES) in long femoropopliteal lesions. Methods A retrospective dual center study …

PURPOSE: To investigate further the safety and efficacy of the sirolimus-eluting SMART
Nitinol Self-expanding Stent by comparison with a bare stent in superficial femoral artery …

BACKGROUND: A randomized prospective study comparing the treatment of superficial
femoral artery occlusive disease percutaneously with an expanded polytetrafluoroethylene …

Background—There are limited data on femoropopliteal artery stent thrombosis (ST), which
is a serious adverse outcome of peripheral artery interventions. Methods and Results …

Background—Primary stenting with self-expanding nitinol stents of the superficial femoral
artery yielded improved morphological and clinical results compared with balloon …

Objectives The aim of this study was to evaluate the 2-year performance of a polymer-based
drug-eluting stent (DES) for the treatment of complex femoropopliteal lesions. Background …

Purpose To report a prospective, single-arm, multicenter clinical study evaluating the Zilver
PTX drug-eluting stent for treating the above-the-knee femoropopliteal segment …